Forest Labs buys Furiex for bowel drug


Forest Laboratories has agreed to buy Furiex pharmaceuticals for $1.1 billion (£650 million) in cash, with a top-up of up to $360 million contingent on approval of Furiex’s irritable bowel syndrome drug eluxadoline.

The drug will mesh quite well with Forest’s other gastrointestinal drug lines, many of which came from its acquisition of Aptalis at the beginning of the year. True to the company’s focus on innovative drugs, Forest has also said that, as soon as the deal goes through, it will sell Furiex’s royalty rights to diabetes drug alogliptin and premature ejaculation remedy Priligy (dapoxetine) to investment firm Royalty Pharma.

There is an interesting twist to the approval contingency payment, too. Because eluxadoline is an opioid receptor agonist, there is a possibility that it will be classified as a controlled substance by the US Drug Enforcement Agency (DEA). If this happens, the value of the top-up payment will go down depending on the level of restriction the DEA imposes.


Related Content

Megamerger brings Actavis into R&D race

25 February 2014 Business

news image

$25bn Forest Labs takeover will see generics giant take on patented products

Business roundup

29 March 2011 Business

news image

Industry news, April 2011

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Chemists zinc up ‘aromatic’ metal cubes

2 March 2015 Research

news image

Metal-organic clusters share electrons between eight covalently linked metal atoms

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent